FDA Bioequivalence Guidance Expands Crossover Designs For ANDA Studies
Guidance “will be especially useful” for planning studies to support postapproval ANDA changes, the agency notes.
You may also be interested in...
Draft highlights bioavailability and bioequivalence concerns unique to new drugs and how they contribute to FDA’s evaluation of safety and effectiveness.
FDA believes that comparative pharmacokinetic studies, instead of comparative clinical endpoint studies, are best for determining bioequivalence of extended- or delayed-release mesalamine products - a reversal of its previous position
Industry also seems supportive of the idea, while Pew touts the power of the power of track-and-trace as a deterrent.